Cancer - Agenus, Inc.

Cancer

Status:

Active, not open to accrual

ClinicalTrials.gov:

NCT05608044

A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) OR INVESTIGATOR’S CHOICE STANDARD OF CARE (REGORAFENIB OR TRIFLURIDINE AND TIPIRACIL) FOR THE TREATMENT OF REFRACTORY METASTATIC COLORECTAL CANCER

Drug

AGEN1181 and AGEN2034

Condition

COLORECTAL CANCER